CLINICAL_TRIALS
trial_result
· 2021-11-30
Clinical Trial Update: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation [Phase 3]
Summary
Phase 3 trial update on apixaban for early prevention of recurrent embolic stroke and hemorrhagic transformation, completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of South Florida | Conditions: Transient Ischemic Attack, Stroke | Phase 3 | Status: COMPLETED | Results posted: 2021-11-30